Pinterest Stock Gains on JPMorgan Rating Upgrade, Price Target Raise
Pinterest shares rose in premarket trading Tuesday after JPMorgan analysts upgraded their rating and lifted their price target on the social media stock.
The analysts lifted the stock to "overweight" from "neutral," and bumped their price target to $40 from $35.
The analysts said Pinterest is improving its user numbers and ad technology, both of which should help drive revenue.Pinterest (PINS) shares rose in premarket trading Tuesday after JPMorgan analysts upgraded their rating and lifted their price target on the social media stock.
The analysts lifted the stock to "Overweight" from "Neutral," and bumped their price target to $40 from $35. That brings JPMorgan in line with most other analysts covering the stock who are tracked by Visible Alpha, as 16 call it a "Buy" and just four a "Hold," with an average price target of $39.75.
They noted that while Pinterest shares are up since the start of the year, they are still about 18% below their February highs while the S&P 500 has recovered to just about 3% below its February record level that month.
Pinterest is "leveraging its full funnel ad approach and automation/AI capabilities—including Performance+—to capture a greater share of ad spending" from advertisers with $1 billion to $30 billion in annual revenue, the analysts wrote. Some larger advertisers are already spending 5% to 10% of their advertising budget on the platform, they added.
The social media platform is growing its monthly active users (MAU) base, with 85% coming directly to Pinterest through its mobile app, the analysts said. They cited that number as a key reason for their upgrade, as Pinterest generates roughly 90% of its revenue through its app, "which limits PINS' exposure to Google & broader overall search disruption," they wrote.
Pinterest shares, which entered the day up 10% this year, rose 4% less than an hour before the opening bell.
Read the original article on Investopedia
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
FTSE 100 LIVE: Stocks rise as traders await ECB interest rate decision
The FTSE 100 (^FTSE) and European stocks rose on Thursday as traders awaited the latest decision on interest rates from the European Central Bank (ECB). Interest rates across the eurozone are likely to be cut by 0.25% again today, as the bank attempts to support the euro economy after the turmoil caused by US president Donald Trump's trade wars. It will be the eighth cut in a year. It comes after eurozone inflation dropped to 1.9% last month, falling below the ECB's 2% target for the first time since last September. Markets are pricing almost a 100% probability of a quarter-point cut, according to Ronald Temple, chief market strategist at Lazard Asset Management. He said: "With ongoing declines in inflation and consistently dovish language from ECB members, a rate cut appears to be a done deal. The ECB has previously described 1.75%–2.25% as the range that would be considered neutral monetary policy. Any signals of a change in this view would be surprising. "I continue to expect rates to be reduced to 1.5% by year end given a more aggressive US trade posture against the European Union. Markets suggest a slightly less dovish outlook with rates ending the year just below 1.6%.' Investors will also focus on the ECB's latest forecasts at the scheduled press conference this afternoon. London's benchmark index (^FTSE) was hovering near the flatline in early trade. Germany's DAX (^GDAXI) rose just 0.2% and the CAC (^FCHI) in Paris also headed 0.2% into the green. The pan-European STOXX 600 (^STOXX) was up 0.2%. Wall Street is set for a positive start as S&P 500 futures (ES=F), Dow futures (YM=F) and Nasdaq futures (NQ=F) were all in the green. The pound was 0.1% up against the US dollar (GBPUSD=X) at 1.3564. Follow along for live updates throughout the day: Stocks in Asia were mixed overnight with the Nikkei (^N225) down 0.5% on the day in Japan, while the Hang Seng (^HSI) rose 0.9% in Hong Kong. The Shanghai Composite ( was 0.2% up by the end of the session. Across the pond on Wall Street, the S&P 500 (^GSPC) eked out a 0.01% gain, and the tech-heavy Nasdaq (^IXIC) was 0.3% higher. The Dow Jones (^DJI) lost 0.2% by the closing bell. Good morning, and welcome back to our markets live blog. As usual we will be taking a deep dive into what's moving markets today, as well as all that's happening across the global economy. The main highlight of the day will be the ECB's latest policy decision and president Lagarde's subsequent press conference. Otherwise, we'll hear from the Fed's Kugler, Harker and Schmid, BoE deputy governor Breeden, and the BoE's Greene. Data releases from the US include the weekly initial jobless claims and the April trade balance. Meanwhile in Europe, there's German factory orders for April, and the May construction PMIs for Germany and the UK. Here's a quick snapshot of what's on the agenda for today: 7am: Trading updates: Mitie, Wizz Air, Workspace, Dr Martens, Young's & Co Brewery 7am: German factory orders for April 9am: UK new car sales report for May 9.30am: UK construction PMI report 1.15pm: European Central Bank interest rate decision 1.30pm: US trade data for April 1.30pm: US weekly jobless claims data 1.45pm: European Central Bank press conferenceStocks in Asia were mixed overnight with the Nikkei (^N225) down 0.5% on the day in Japan, while the Hang Seng (^HSI) rose 0.9% in Hong Kong. The Shanghai Composite ( was 0.2% up by the end of the session. Across the pond on Wall Street, the S&P 500 (^GSPC) eked out a 0.01% gain, and the tech-heavy Nasdaq (^IXIC) was 0.3% higher. The Dow Jones (^DJI) lost 0.2% by the closing bell. Good morning, and welcome back to our markets live blog. As usual we will be taking a deep dive into what's moving markets today, as well as all that's happening across the global economy. The main highlight of the day will be the ECB's latest policy decision and president Lagarde's subsequent press conference. Otherwise, we'll hear from the Fed's Kugler, Harker and Schmid, BoE deputy governor Breeden, and the BoE's Greene. Data releases from the US include the weekly initial jobless claims and the April trade balance. Meanwhile in Europe, there's German factory orders for April, and the May construction PMIs for Germany and the UK. Here's a quick snapshot of what's on the agenda for today: 7am: Trading updates: Mitie, Wizz Air, Workspace, Dr Martens, Young's & Co Brewery 7am: German factory orders for April 9am: UK new car sales report for May 9.30am: UK construction PMI report 1.15pm: European Central Bank interest rate decision 1.30pm: US trade data for April 1.30pm: US weekly jobless claims data 1.45pm: European Central Bank press conference
Yahoo
an hour ago
- Yahoo
European markets edge higher as investors eye ECB interest rate decision
Markets are widely expecting the European Central Bank (ECB) to cut interest rates again at its monetary policy meeting later today. "At its most recent meeting in April, the ECB reduced its key interest rates by 25 basis points, bringing the deposit facility rate to 2.25%. Markets are now pricing in another cut in June, though expectations for further easing beyond that remain uncertain. A potential pause in July is gaining traction, as the ECB evaluates incoming economic data and inflation dynamics," market analysts at said. The latest decision will come as inflation in the euro area cooled more than expected in May, bolstering expectations that the ECB will announce another interest rate cut. Annual consumer price growth slowed to 1.9% in May, down from 2.2% in April, according to a flash estimate from Eurostat this week. The figure came in below economists' forecast of 2%, and marks the first time inflation has dipped below the ECB's 2% target since September 2024. The decline in headline inflation suggests that business uncertainty, partly driven by renewed global trade tensions and soft consumer demand, is weighing on pricing power across sectors. Core inflation, which strips out volatile food and energy prices, also showed signs of easing. It slowed to 2.4% in May, from 2.7% in April, falling below expectations of 2.5%. On a monthly basis, core prices rose by just 0.1%. Related Eurozone inflation falls below ECB 2% target in May: Rate cut in sight Meanwhile, Asian shares were mixed on Thursday, as Wall Street's big recent rally lost some momentum following a pair of potentially discouraging reports on the American economy. US futures edged lower and oil prices declined. Japan's benchmark Nikkei 225 shed 0.2% to 37,658.46, while Australia's S&P/ASX 200 declined nearly 0.1% to 8,535.10. In South Korea, the Kospi jumped 2.1% to 2,829.48 after the country's new president and leading liberal politician Lee Jae-myung began his term, vowing to restart talks with North Korea and beef up a trilateral partnership with the US and Japan. Hong Kong's Hang Seng gained 0.9% to 23,856.54, while the Shanghai Composite was little changed, inching down less than 0.1% to 3,374.30. On Wednesday, the S&P 500 finished the day virtually unchanged at 5,970.81 and remained 2.8% below its all-time high. The Dow Jones Industrial Average fell 0.2% to 42,427.74, and the tech-heavy Nasdaq composite added 0.3% to 19,460.49. The action was stronger in the bond market, where Treasury yields tumbled following weaker-than-expected economic updates. In other dealings early Thursday morning, benchmark US crude fell 8 cents to $62.77 a barrel. Brent crude, the international standard, edged up 1 cent to $64.87 a barrel. The US dollar rose to 142.87 Japanese yen from 142.78 yen. The euro cost $1.1413, little changed from $1.1418.
Yahoo
an hour ago
- Yahoo
Here Are All 6 Stocks I've Bought Through 5 Months of 2025
President Donald Trump's tariff-induced stock swoon rolled out the red carpet for investors to snag high-quality stocks at a discount. Buying stocks and holding those positions for multiple years is ingrained into my investment philosophy. High-yield dividend stocks, a deeply-discounted legal monopoly, a uniquely-positioned growth stock, and a handful of turnaround candidates were on my buy list through May. 10 stocks we like better than Pfizer › It's been a wild ride for the stock market through the first five months of 2025. As of mid-February, Wall Street's major stock indexes could do no wrong, with the benchmark S&P 500 vaulting to an all-time record-closing high. But over the next two months, tariff-related uncertainty pushed the Nasdaq Composite into its first bear market in three years, and weighed the S&P 500 down to near-bear market territory. Historically, double-digit percentage declines in the major stock indexes represent ideal opportunities for long-term investors to pounce. As of this writing on June 2, I hold 38 positions in my portfolio -- 37 stocks and one exchange-traded fund (ETF) -- and only four of these stakes have been held for less than a year. Buying and holding stocks for years is ingrained into my investment philosophy. With volatility begetting opportunity, here are all six stocks I've bought through the first five months of 2025. One of the new holdings I added to my portfolio this year is pharmaceutical titan Pfizer (NYSE: PFE). The two separate purchases I've made gave me a cost basis of $23.47 per share, which is a penny above where shares closed on June 2. What makes Pfizer so attractive is that it's been punished for its own success. After generating north of $56 billion in combined sales for its COVID-19 vaccine (Comirnaty) and oral therapy (Paxlovid) in 2022, combined sales tumbled to around $11 billion in 2024. But even if these sales fall again in 2025, Pfizer has, collectively, grown its net product revenue by more than 50% over four years. The shortsightedness of select investors is creating a significant buying opportunity for long-term-minded investors. Additionally, Pfizer's oncology segment can be a key growth driver in the years to come. It completed a $43 billion acquisition of cancer-drug developer Seagen in December 2023. This deal added more than $3 billion in immediate sales to Pfizer's oncology portfolio, as well as vastly expanded its pipeline. With Pfizer also targeting billions of dollars in annual cost-savings, a forward price-to-earnings (P/E) ratio of less than 8, coupled with a dividend yield of more than 7%, was too enticing to pass up. The stock I've unquestionably put the most money to work in this year is adtech company PubMatic (NASDAQ: PUBM). I've more than doubled my stake in the company since late February, with a cost basis from shares purchased this year of $9.29. PubMatic is perfectly positioned to take advantage of businesses shifting their ad dollars from print and billboards to digital channels, such as video, mobile, and connected TV (i.e., streaming content). PubMatic's cloud-based programmatic ad platform assists publishers in selling their digital display space. Aside from digital advertising offering sustained double-digit sales growth, PubMatic will benefit from its decision to build out its cloud infrastructure platform. Though it would have been easier to rely on a third party, taking the time to build out this critical infrastructure will now allow PubMatic to hang onto more of its revenue as it scales. This should lead to superior margins, relative to other sell-side providers. Furthermore, PubMatic is swimming with cash. It's been generating positive operating cash flow for a decade and has been aggressively repurchasing its own stock. When backing out its cash position, investors are paying less than $9 per share for a company fully capable of producing more than $1 in earnings per share in a thriving economy. Although the stock market is historically pricey, select value stocks can be found. Satellite-radio operator Sirius XM Holdings (NASDAQ: SIRI) certainly fits the bill. The one add I made to my existing Sirius XM stake came at $19.28 per share on April 4. The great thing about Sirius XM is that it's a legal monopoly. Even though it's still fighting for listeners with traditional radio companies, being the only licensed satellite-radio operator does afford the company some degree of subscription pricing power. Even more important, Sirius XM generates the bulk of its revenue differently than terrestrial and online radio companies. Whereas the latter are heavily reliant on advertising, Sirius XM generates a little over three-quarters of its net sales from subscriptions. When recessions do occur, subscribers are far less likely to cancel their service than businesses are to meaningfully pare back their ad spending. On paper, this makes Sirius XM's operating cash flow far more predictable. Sirius XM's forward P/E of 7, when combined with a dividend yield that's currently above 5%, makes for a tantalizing buy. Semiconductor behemoth Intel (NASDAQ: INTC) is another long-term holding that I chose to add to during President Donald Trump's tariff-induced market swoon. The lone addition was made on April 8 at $18.56. My wager on Intel is that management can eventually turn around a business that was late to the artificial intelligence (AI) party. While Intel's graphics processing units (GPUs) haven't exactly flown off the shelves like Nvidia's hardware, AI is a massive enough addressable market that even latecomers with established brand names can thrive. Despite its GPU tardiness, Intel's central processing units (CPUs) continue to play a key role in high-compute data centers and traditional desktops/laptops. Even with Advanced Micro Devices chipping away at Intel's once monopoly like CPU market share, Intel remains the decisive leader. The robust cash flow generated from its CPU sales can help Intel redirect capital to higher-growth initiatives. While trading in the mid-$18s, Intel stock was also nearing its tangible book value and had fallen 19% below its listed book value, as of the most recent quarter. Though book value is just one of many valuation measures, I believe there are enough levers to pull and long-term catalysts for Intel stock to bounce back. Specialty drugmaker BioMarin Pharmaceutical (NASDAQ: BMRN) is another holding I've purchased for the first time in 2025. My lone purchase occurred on April 8 at a cost basis of $56.01. One of the variables that makes BioMarin such an attractive investment is its focus on ultrarare diseases. Though the clinical success rate in treating rare diseases can be dicey, positive clinical trials can lead to approved therapies that face little or no competition. What's more, insurers rarely push back on high list prices for rare-disease drugs that have no alternatives. BioMarin's shining star for the moment is Voxzogo, a drug used to treat achondroplasia, which is a common type of dwarfism. A combination of strong pricing power and label expansion opportunities should lead to Voxzogo eventually topping $1 billion in annual sales. Further, BioMarin is targeting $4 billion in annual sales by 2027, which would be up from $2.85 billion in reported sales for 2024. Given the exceptionally high margins associated with ultrarare-disease drugs, BioMarin's forward P/E of 10.6, and its projected low-double-digit sales growth rate, make its stock quite the bargain. Last but not least, I added to my existing position in edge cloud-computing company Fastly (NYSE: FSLY) during the Trump tariff tumble. The only addition came on April 4 at a cost of $5.08 per share. Similar to Intel, Fastly is a work in progress that isn't going to right itself overnight. The investment thesis here is that as businesses shift their data and that of their customers online and into the cloud, demand for rapid and secure content delivery network (CDN) services will only increase. Fastly aggressively expanded the capabilities of its CDN following the pandemic. Although not all of Fastly's key performance indicators (KPIs) have moved in the right direction, some of the most important KPIs suggest management is making the right moves. For instance, its revenue retention rate is locked in at 99% or higher, and its enterprise customer count, while a bit volatile, has been chopping its way higher. Perhaps the most exciting number in Fastly's latest quarter is its remaining performance obligation (i.e., its backlog), which surged above $300 million. Considering that Fastly is generating positive operating cash flow, the foundation for future profits has been laid. Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $656,825!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $865,550!* Now, it's worth noting Stock Advisor's total average return is 994% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Sean Williams has positions in BioMarin Pharmaceutical, Fastly, Intel, Pfizer, PubMatic, and Sirius XM. The Motley Fool has positions in and recommends Advanced Micro Devices, Fastly, Intel, Nvidia, Pfizer, and PubMatic. The Motley Fool recommends BioMarin Pharmaceutical and recommends the following options: short August 2025 $24 calls on Intel. The Motley Fool has a disclosure policy. Here Are All 6 Stocks I've Bought Through 5 Months of 2025 was originally published by The Motley Fool Sign in to access your portfolio
